# Window of Opportunity Trial of Nivolumab and Tadalafil in Patients With Squamous Cell Carcinoma of the Head and Neck

> **NCT03238365** · EARLY_PHASE1 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University** · enrollment: 50 (actual)

## Conditions studied

- Lip, Oral Cavity and Pharynx
- Larynx

## Interventions

- **BIOLOGICAL:** Nivolumab
- **DRUG:** Tadalafil
- **PROCEDURE:** Therapeutic Conventional Surgery

## Key facts

- **NCT ID:** NCT03238365
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-10
- **Primary completion:** 2019-07-30
- **Final completion:** 2022-09-08
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2025-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03238365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03238365, "Window of Opportunity Trial of Nivolumab and Tadalafil in Patients With Squamous Cell Carcinoma of the Head and Neck". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03238365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*